Compare RETO & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RETO | AIDX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | China | United States |
| Employees | N/A | 14 |
| Industry | Multi-Sector Companies | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 9.2M |
| IPO Year | 2016 | N/A |
| Metric | RETO | AIDX |
|---|---|---|
| Price | $2.68 | $0.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 52.9K | ★ 425.3K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $0.51 |
| 52 Week High | $4.66 | $14.09 |
| Indicator | RETO | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 58.54 | 36.53 |
| Support Level | $2.49 | $0.54 |
| Resistance Level | $2.80 | $1.00 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 59.32 | 21.25 |
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Equipment and technical service segment, and Craft beer segment. The company earns its revenue from the Equipment and technical service segment. Geographically, it derives a majority of its revenue from China.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.